Alzamend Neuro Inc. (NASDAQ: ALZN) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT ALZAMEND NEURO INC.

Alzamend Neuro Inc. (NASDAQ: ALZN)
Listen to this Section


$1.11
-0.0300 ( -2.63% ) 10.2K

Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

Clinical Trial Pipeline Stages


Drug Name Stage
AL001DetailsAlzheimer's disease Phase 2
AL001DetailsMajor depressive disorder Phase 2
AL001DetailsPost-traumatic stress disorder Phase 2
AL001DetailsBipolar disease Phase 2
ALZN002DetailsAlzheimer's disease, Dementia Phase 1/2

Market Data


Open $1.11
Previous Close $1.14
Volume 10.2K
Market Cap $4.38M
Day Range $1.10 - $1.15
52 Week Range $0.84 - $4.00
Shares Outstanding 3.80M
Change % -2.63%
Net Change ▼ -0.0300
Insider Ownership 0.00%
Exchange NASDAQ
SectorHealthcare
IndustryMedicinal Chemicals and Botanical Products
IPO Year2021
CountryUnited States
UnderwriterSpartan Capital Securities, more

Insider Ownership Transactions

Total Amount Purchased: -597,534.00

Date Type Amount Purchased Purchaser
2023-09-26 Buy 53000.00 Katzoff David J

SEC Filings


Form Type Description Pages Date
8-k 8K-related 11 Mar 20, 2026
10-q Quarterly Reports 53 Mar 11, 2026
8-k 8K-related 18 Mar 06, 2026
424b5 Other 6 Mar 06, 2026
def Proxies and info statements 21 Feb 26, 2026
defa14a Other 3 Feb 26, 2026
pre Proxies and info statements 4 Feb 09, 2026
4 Insider transactions 1 Dec 30, 2025
4 Insider transactions 1 Dec 23, 2025
10-q Quarterly Reports 53 Dec 09, 2025

Latest News


× Before browsing our site, please accept our cookies policy